BNB Plus Corp. is a biotechnology company, which engages in the development and commercialization of technologies to produce and detect deoxyribonucleic acid and ribonucleic acid. The company is headquartered in Stony Brook, New York and currently employs 26 full-time employees. The company went IPO on 2001-08-24. Its segments include digital asset treasury, therapeutic deoxyribonucleic acid (DNA) production services, DNA tagging and security products and services. Its digital asset treasury segment is engaged in managing digital assets. Its therapeutic DNA production services segment is engaged in nucleic-acid production solutions for the biopharmaceutical and diagnostics industries, including LineaDNA, LineaRNAP and LineaIVT. Its DNA tagging and security products and services segment is engaged in the manufacture and detection of DNA for industrial supply chains and security services. Its subsidiary LineaRx, Inc., is engaged in commercializing nucleic acid production solutions for the biopharmaceutical and diagnostics markets.
최신 재무제표(Form-10K)에 따르면, BNB Plus Corp의 총 자산은 $0이며, 순손실입니다.
BNBX의 주요 재무 비율은 무엇인가요?
BNB Plus Corp의 유동비율은 0이고, 순이익률은 0, 주당 매출은 $0입니다.
BNB Plus Corp의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
BNB Plus Corp 주요 수익원은 Deoxyribonucleic Acid Tagging and Security Products이며, 최신 수익 발표에서 수익은 1,148,817입니다. 지역별로는 Asia and Other이 BNB Plus Corp의 주요 시장이며, 수익은 1,020,556입니다.